Background-Contemporary outcomes of percutaneous transluminal angioplasty for the treatment of infrapopliteal atherosclerotic lesions are not well characterized. Hence, a systematic review and meta-analysis was performed to determine the safety and effectiveness of this approach in patients with advanced below-the-knee arterial disease. Methods and Results-MEDLINE and EMBASE databases were searched for contemporary studies (2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015) on the effects of percutaneous transluminal angioplasty for the treatment of infrapopliteal lesions. A random effects meta-analysis model was used to analyze procedural (technical success, flow-limiting dissection, provisional stent placement) and longterm (primary patency, repeat revascularization, major amputation, all-cause mortality) outcomes. Ultimately, 52 studies encompassing 6769 patients with 9399 below-the-knee lesions were included in the analysis. Technical success was 91.1% (95% confidence interval [CI], 88.8-93.0), and the incidence of flow-limiting dissections and bailout stenting was 5.6% (95% CI, 3.2-9.8) and 9.1% (95% CI, 6.3-12.9), respectively. Outcomes at 1 year were primary patency, 63.1% (95% CI, 57.3-68.6); repeat revascularization, 18.2% (95% CI, 14.5-22.6); major amputation, 14.9% (95% CI, 12.3-18.0); and all-cause mortality, 15.1% (95% CI, 12.8-17.7). Significant heterogeneity and publication bias were observed for most percutaneous transluminal angioplasty outcomes. Conclusions-Contemporary studies of the use of percutaneous transluminal angioplasty as primary treatment for patients with infrapopliteal arterial disease reveal suboptimal procedural and 1-year clinical outcomes. (Circ Cardiovasc Interv. 2016;9:e003468.
C ritical limb ischemia represents the terminal stage of obstructive, atherosclerotic, peripheral arterial disease. Patients affected by critical limb ischemia are the most complex subset of those with peripheral arterial disease and typically bear the long-term pathological consequences of hypertension, hyperlipidemia, diabetes mellitus, and renal failure. Anatomically, they frequently present with infrapopliteal disease, characterized by diffuse, multilevel, and multivessel calcific involvement. Due in part to the heterogeneous complexity of these patients, there is a drought of generalizable scientific evidence to support the use of percutaneous revascularization, 1 and the optimal treatment modality remains controversial. Currently, percutaneous transluminal angioplasty (PTA) is the endovascular modality used as the standard of care 2 ; however, PTA outcomes in this patient population remain suboptimal. 3 A recent meta-analysis revealed that PTA in below-the-knee (BTK) lesions results in inferior procedural and short-term outcomes relative to other endovascular modalities. 4 In 2008, Romiti et al 5 authored the only meta-analysis to date that has comprehensively assessed longterm outcomes in infrapopliteal PTA studies. Given the paucity of modern data reflective of the current status of endovascular interventions for the treatment of atherosclerotic infrapopliteal disease, we conducted a systematic review and meta-analysis of contemporary studies on the use and outcomes of PTA in this population, while attempting to comprehensively characterize potential sources of data heterogeneity.
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Methods
Eligibility Criteria and Information Sources
This study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). 6 Medline and EMBASE databases were searched for randomized or nonrandomized controlled studies and prospective or retrospective case series published between January 2005 and October 2015 on Meta-Analysis of Infrapopliteal PTA the effects of PTA for the treatment of infrapopliteal lesions. The details of the database search strategy are listed in Table I in the Data Supplement. Additionally, manual searches were conducted using the Directory of Open Access Journals, Google Scholar, and the reference lists of included papers and other relevant meta-analyses.
Study Selection
One reviewer selected studies for inclusion in the review. Articles were then independently assessed by a second reviewer, who confirmed eligibility. Titles were initially screened to exclude all non-English, review articles, commentaries, letters, and case reports. Full texts of the included manuscripts were retrieved and reviewed. Studies of PTA in BTK lesions were included regardless of study design if BTK-specific outcomes were reported. Studies were excluded if all treated lesions were inframalleolar; if all patients were included solely based on previous procedural success or failure; if stents were routinely placed; or if a kin relationship was identified (multiple publications describing the same or overlapping series of patients). In these instances, we included only the manuscript with the largest sample size.
Data Extraction
A database was developed, pilot-tested, and subsequently refined to develop the final source for data extraction. Two authors independently extracted the data; discrepancies were resolved by consensus.
Outcomes
The main outcomes of the present study included immediate procedural (technical success, flow-limiting dissection, provisional stent placement) and 1-year outcomes (primary patency, repeat revascularization, major amputation, all-cause mortality). Outcome definitions followed the recommendations of Diehm et al 7 unless described otherwise. As noted for primary patency and repeat revascularization in Table II in the Data Supplement, outcome definitions were inconsistent. For this meta-analysis, reported outcomes were based on the number of respective studies that published the specified finding, despite these inconsistences.
Data Analysis
A random effects meta-analysis model was selected a priori based on the assumption that treatment effects were heterogeneous given the differences in study designs and patient characteristics among studies. Denominators were adjusted, where appropriate, to include the number of patients, procedures, limbs, or lesions. One-year data were extracted from studies with mean follow-up ranging from 9 to 15 months or from studies with longer follow-up where 1-year outcomes were explicitly reported. Kaplan-Meier survival estimates were converted to proportions using the number enrolled, number at risk, or follow-up distribution (when number at risk was not reported), and the survival estimate at the respective time point. For each outcome, the incidence and 95% confidence interval were calculated. A forest plot was used to illustrate the individual study findings and the random effects meta-analysis results. We used the I 2 statistic to estimate heterogeneity of effects across studies with values of ≤25%, 50%, and ≥75% representing low, moderate, and
WHAT IS KNOWN
• Although PTA is the endovascular modality used as the standard of care in the treatment of patients with infrapopliteal arterial disease, the optimal treatment modality remains controversial.
WHAT THE STUDY ADDS
• This study reports the largest known meta-analysis in patients treated with PTA for infrapopliteal atherosclerotic lesions.
• Contemporary studies of PTA in infrapopliteal arteries report suboptimal short-term and 1-year clinical outcomes.
• Significant heterogeneity was observed for all main outcomes and hinders interpretability of current findings.
• Large-scale, multicenter, prospective studies evaluating infrapopliteal treatment modalities are essential to advance uniform treatment standards. high inconsistency, respectively. 8 Publication bias was visually assessed with funnel plots (not shown) and quantitatively assessed using the Egger regression test. 9 Subgroup analyses were undertaken to explore potential sources of heterogeneity in 1-year outcomes. All analyses were performed using Comprehensive Meta-Analysis (version 2.2, Biostat, Englewood, NJ).
Results
Study Selection
After screening 1068 studies, 156 full-text articles were reviewed for eligibility. The most common reasons for study exclusion were BTK-specific outcomes not reported (71 studies), kin relationships (23 studies 
Study Characteristics
Most studies included in this review were conducted in European countries (63%), at single centers (83%), and using retrospective designs (65%). Sample sizes varied considerably, ranging from 15 to 1268. The median treatment period of included studies ranged from 1992 to 2012 (Table III in the Data Supplement).
Patient and Lesion Characteristics
Mean patient age was 70 years with males accounting for 66% of patients. The most commonly reported comorbidities were diabetes mellitus (75%), hypertension (75%), and hyperlipidemia (53%). Most (97%) patients had critical limb ischemia (Rutherford Classification IV-VI). Treated lesions were most commonly located in the anterior tibial artery (37%), peroneal artery (28%), or posterior tibial artery (22%). Most treated lesions were calcified (61%) or occluded (52%), with a mean length of 105 mm (range: 12-350 mm; Table 1 ).
Procedural Outcomes
In 44 studies, technical success with PTA was 91.1% (95% CI, 88.8-93.0). In 24 studies, the incidence of flow-limiting dissection was 5.6% (95% CI, 3.2-9.8), which were treated with provisional stent placement (92%) or dilatation only (8%). Overall, the incidence of provisional stent placement was 9.1% (95% CI, 6.3-12.9) in 36 studies.
One-Year Outcomes
In 19 studies, primary patency at 1 year was 63.1% (95% CI, 57.3-68.6; Figure 1 ). Significant heterogeneity in primary patency outcomes was identified among studies (I 2 =86%, P<0.001); no publication bias was evident (Egger's P=0. 41 ).
In 27 studies, the rate of repeat revascularization at 1 year was 18.2% (95% CI, 14.5-22.6; Figure 2 ). There was significant inconsistency (I 2 =80%; P<0.001) and evident publication bias (Egger's P=0.04) identified among studies for this outcome. In 37 studies, the major amputation rate at 1 year was 14.9% (95% CI, 12.3-18.0; Figure 3 ). There was significant inconsistency (I 2 =82%; P<0.001) with evident publication bias (Egger's P<0.001). In 33 studies, all-cause 
Subgroup Analysis of 1-Year Outcomes
Subgroup analyses were performed to explore potential sources of heterogeneity in 1-year outcomes. Higher primary patency rates were identified in studies with larger versus smaller sample sizes (69.1% versus 53.1%), studies that enrolled younger patients (75.0% versus 61.3%), and those that enrolled a lower percentage of diabetic patients (69.9% versus 55.9%) and a higher percentage with renal disease (71.1% versus 55.7%). No variables influenced the incidence of repeat revascularization. The incidence of major amputation was lower in prospective studies (6.2% versus 18.6%), multicenter studies (6.2% versus 16.8%), and in studies with a higher percentage of occluded lesions (9.3% versus 17.8%).
One-year mortality rates were lower in studies with higher percentage of male patients, lower percentage with renal disease, longer lesion lengths, lower percentage of calcified lesions, and higher percentage of occluded lesions. Many comparisons were limited by nonreporting of the variables of interest ( Table 2 ).
Discussion
This study reports the largest known meta-analysis in patients treated with PTA for infrapopliteal atherosclerotic lesions. In 52 studies with nearly 7000 total patients, PTA was associated with 91% technical success, 5.6% flow-limiting dissection, and 9.1% provisional stent placement. Additionally, primary patency was 63%, and repeat revascularization, major amputation, and all-cause mortality through 1 year ranged from 15% to 18%, respectively. Significant heterogeneity was identified for all 1-year outcomes. Subgroup analysis identified several factors that were associated with clinical outcomes, although some of the findings were counterintuitive. Specifically, studies with a higher percentage of occluded lesions and longer lesion lengths reported lower 1-year mortality rates. We performed an exploratory post hoc analysis that showed studies with longer lesions, and greater occlusive disease tended to report less calcification. Because 1-year mortality rates were almost 50% lower in studies with more occlusive disease, it seems that the influences of lesion length and occlusive disease on mortality are confounded by the deleterious effects of arterial calcification. Additionally, there was a moderate-to-strong positive association among studies between proportion of patients with calcified lesions and those with renal disease (r=0.64). Although a more robust analysis was not possible given limited data availability, it seems that the inter-related effects of arterial calcium and renal disease may have been primary drivers of mortality risk in this meta-analysis.
In 2008, Romiti et al 5 published the only meta-analysis to date that comprehensively assessed long-term outcomes of infrapopliteal PTA studies. Their meta-analysis included studies published between 1990 and 2006, whereas the current meta-analysis included those published between 2005 and 2015, with 43 (83%) published after 2006. Consequently, there is little overlap between these 2 reports. Despite the disparate inclusive periods, the outcomes of each meta-analysis are consistent with one another. Comparing 1-year outcomes from the current meta-analysis to their results, primary patency was 63% versus 58%, major amputation was 15% versus 14%, and all-cause mortality was 15% versus 13%. Additionally, technical success rates were comparable between studies (91% versus 89%). These findings suggest that outcomes of PTA for infrapopliteal disease have not changed over the last decade, despite newer techniques, approaches, and available technologies. Comparing baseline characteristics of our study that were common to those of Romiti, main findings included age (70 years in both), diabetes mellitus (75% versus 61%), hypertension (75% versus 54%), smoking (40% versus 50%), renal disease (34% versus 23%), tissue loss (79% versus 76%), and occlusive disease (52% versus 41%). Therefore, it is plausible that the lack of outcome improvement over time with PTA may be influenced by treatment of patients with increasingly more comorbidities and complex lesion characteristics.
Over the last 10 years, there has been an exponential increase in the body of knowledge and understanding of the pathophysiological processes governing critical limb ischemia. These advances span the spectrum from enhanced disease awareness, screening, and diagnosis to the implementation of standardized protocols for clinical and noninvasive follow-up, wound care, and concomitant risk factor treatment, as well as to the design of novel and disruptive technologies (atherectomy, cryoplasty, focal force balloons, crossing, and reentry devices), 61 which have provided operators with an unprecedented ability to revascularize lesions in patients who were previously thought to be no option cases. As the complexity of patients undergoing infrapopliteal endovascular treatment continues to rise, it is possible that PTA outcomes have plateaued. Largescale, multicenter, prospective studies of currently available disruptive therapies with inclusion criteria that encompass the real-world patient are imperative to generate relevant and generalizable data that can be used to develop evidencedbased standards to treat this multifaceted disease.
Study Limitations
Within the meta-analysis, heterogeneity and publication bias were frequently observed, which confounded data interpretation, and there was considerable variation in the completeness of data reported among studies. In addition, inclusion of PTA data from nonrandomized, noncontrolled, and retrospective studies may have introduced bias into the results. Unreported confounding factors such as patient and procedural (lesion, techniques) characteristics, medical history, disease severity, and physician and center experience may diminish the generalizability of the outcomes. This was limited by extracting possible confounders and performing subgroup analyses to determine their influence on primary patency. Unfortunately, the number of available studies with complete data was inadequate for some comparisons.
Conclusions
Contemporary studies of PTA in infrapopliteal arteries reveal suboptimal short-term and 1-year clinical outcomes; however, significant heterogeneity for main outcomes hinders interpretability and generalizability of current findings. Procedural failures and loss of patency remain therapeutic challenges to be solved in this expanding patient population. Large-scale, multicenter, prospective studies that systematically evaluate existing infrapopliteal treatment modalities are needed to advance contemporary evidenced-based treatment standards.
